- Home
- Life Sciences
- Pharmaceutical
- Pathology
- Global Pathology Analysis & Statistics, March 2013 (p2)
Talk to Alison
00 1 718 618 48 97
Search inside this page
Publication dates
Publishers
- Global Markets Direct (1 556)
- Global Data (599)
- BCC Research (36)
- Daedal Research (2)
- GBI Research (35)
-
- Global Industry Analysts (1)
- Transparency Market Research (1)
- TriMark Publications (4)
- World Market Intelligence Ltd (9)
- Business Monitor International (45 105)
- Datamonitor (94)
- Timely Data Resources Inc. (29)
- Visiongain (29)
- Global Industry Analyst (21)
- Frost & Sullivan (15)
- Kalorama Information (14)
- Espicom Business Intelligence (12)
- Koncept Analytics (12)
- Infiniti Research Limited (9)
- Life Science Analytics (LSA) (9)
- Sociable Pharma (9)
- SCRIP Insights (7)
- MarketsandMarkets (4)
- IData Research, Inc. (4)
- Aruvian's R'search (3)
- ICD Research (3)
- MarketLine (3)
- Renub Research (3)
- Arrowhead (2)
- Firstword Pharma (2)
- RNCOS (2)
- Venture Planning Group (2)
- Bioseeker (1)
- Business Review (1)
- CHI Insight Pharma Reports (1)
- France Innovation Scientifique et Transfert (1)
- La Merie Publishing (1)
- Urch Publishing (1)
- VacZine Analytics Group Of Assay Advantage Ltd (1)
- WinterGreen Research (1)
- Zzz FACT Research (1)
All regions
data types
Free Market Research Guides to Download
Global Pathology Analysis & Statistics, March 2013 (p2)
You might be interested in: cancer, breast cancer, prostate cancer, more »
» Purchase Premium Reports
31-70 of about 2 500 reports
Masitinib (Multiple Sclerosis) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- March 2013
- by Global Data
Masitinib (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Masitinib (Multiple Sclerosis) - Forecast and Market ...
- Industries : Pathology
- Countries : Canada, Spain, Italy, France, Germany, Japan, India, China, World, United States, Europe, United Kingdom
Daclizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- March 2013
- by Global Data
Daclizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Daclizumab (Multiple Sclerosis) - Forecast and Market ...
- Industries : Pathology
- Countries : Canada, Spain, Italy, France, Germany, Japan, India, China, World, United States, Europe, United Kingdom
Ocrelizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- March 2013
- by Global Data
Ocrelizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Ocrelizumab (Multiple Sclerosis) - Forecast and Market ...
- Industries : Pathology
- Countries : United States, Canada, Spain, Italy, France, Germany, Japan, India, China, World, Europe, United Kingdom
Siponimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- March 2013
- by Global Data
Siponimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Siponimod (Multiple Sclerosis) - Forecast and Market ...
- Industries : Pathology
- Countries : Canada, Spain, Italy, France, Germany, Japan, India, China, World, United States, Europe, United Kingdom
NU-100 (Multiple Sclerosis) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- March 2013
- by Global Data
NU-100 (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?NU-100 (Multiple Sclerosis) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : United States, Canada, Spain, Italy, France, Germany, Japan, India, China, World, Europe, United Kingdom
Laquinimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- March 2013
- by Global Data
Laquinimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Laquinimod (Multiple Sclerosis) - Forecast and Market ...
- Industries : Pathology
- Countries : Canada, Spain, Italy, France, Germany, Japan, India, China, World, United States, Europe, United Kingdom
Lemtrada (Multiple Sclerosis) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- March 2013
- by Global Data
Lemtrada (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Lemtrada (Multiple Sclerosis) - Forecast and Market ...
- Industries : Pathology
- Countries : United States, Canada, Spain, Italy, France, Germany, Japan, India, China, World, Europe, United Kingdom
Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- May 2013
- by Global Data
Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Bosulif (Chronic Myeloid Leukemia) - Forecast and ...
- Industries : Pathology
- Countries : World, Europe, United States, Spain, Italy, France, Germany, Japan, United Kingdom
Aubagio (Multiple Sclerosis) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- March 2013
- by Global Data
Aubagio (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Aubagio (Multiple Sclerosis) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : Canada, Spain, Italy, France, Germany, Japan, India, China, World, Europe, United States, United Kingdom
Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- March 2013
- by Global Data
Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Gilenya (Multiple Sclerosis) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : Canada, Japan, World, United States, Spain, Italy, France, Germany, India, China, Europe, United Kingdom
Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- May 2013
- by Global Data
Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Synribo (Chronic Myeloid Leukemia) - Forecast and ...
- Industries : Pathology
- Countries : World, Spain, Italy, France, Germany, Japan, United States, Europe, United Kingdom
Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- May 2013
- by Global Data
Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Iclusig (Chronic Myeloid Leukemia) - Forecast and ...
- Industries : Pathology
- Countries : World, Spain, Italy, France, Germany, Japan, Europe, United States, United Kingdom
Copaxone (Multiple Sclerosis) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- March 2013
- by Global Data
Copaxone (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Copaxone (Multiple Sclerosis) - Forecast and Market ...
- Industries : Pathology
- Countries : Canada, Spain, Italy, France, Germany, Japan, India, China, World, United States, Europe, United Kingdom
Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- March 2013
- by Global Data
Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Rebif (Multiple Sclerosis) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : United States, Canada, Spain, Italy, France, Germany, Japan, India, China, World, Europe, United Kingdom
Tysabri (Multiple Sclerosis) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- March 2013
- by Global Data
Tysabri (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Tysabri (Multiple Sclerosis) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : Canada, Spain, Italy, France, Germany, Japan, India, China, World, United States, Europe, United Kingdom
Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- March 2013
- by Global Data
Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Avonex (Multiple Sclerosis) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : United States, Canada, Spain, Italy, France, Germany, Japan, India, China, World, Europe, United Kingdom
Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- March 2013
- by Global Data
Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Betaseron/Betaferon (Multiple Sclerosis) ...
- Industries : Pathology
- Countries : World, United States, Canada, Spain, Italy, France, Germany, Japan, India, China, Europe, United Kingdom
Hemoglobin A1c Testing Markets
- $ 3 400
- Industry report
- March 2013
- by TriMark Publications
Hemoglobin A1c (HbA1c) testing is the most recent major technology to have entered the diabetes testing market. As the global prevalence of diabetes mellitus continues to increase rapidly, with more than ...
- Industries : Pathology
- Countries : United States, World
PharmaPoint: Osteoporosis - Current and Future Players
- $ 2 995
- Industry report
- February 2013
- by Global Data
PharmaPoint: Osteoporosis - Current and Future Players Summary Osteoporosis is caused by the gradual weakening of the bones due to abnormal osteocyte function, which occurs as a result of hormonal fluctuations, ...
- Industries : Pathology
- Countries : World
PharmaPoint: Multiple Sclerosis - Current and Future Players
- $ 2 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - Current and Future Players Summary GlobalData has released its pharma report, ?PharmaPoint: Multiple Sclerosis - Current and Future Players?. The report is a vital source ...
- Industries : Pathology
- Countries : World
PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players
- $ 2 995
- Industry report
- May 2013
- by Global Data
PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players Summary GlobalData has released its pharma report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players?. ...
- Industries : Pathology
- Countries : World
Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2013
- $ 2 500
- Industry report
- February 2013
- by Global Data
Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, ?Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, ...
- Industries : Pathology
- Countries : World
Pathology Industry: Non-Small Cell Lung Cancer - Pipeline Review, H1 2012
- $ 2 500
- Industry report
- February 2013
- by Global Markets Direct
This report provides data on the therapeutic development for Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key ...
- Industries : Pathology
- Countries : United States, World
Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2013
- $ 2 500
- Industry report
- March 2013
- by Global Data
Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, ?Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials ...
- Industries : Pathology
- Countries : World, United States
World Pathology: Metastatic Lung Cancer - Pipeline Review, H1 2012
- $ 2 000
- Company report
- April 2013
- by Global Markets Direct
This report provides data on the therapeutic development for Metastatic Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...
- Industries : Pathology
- Countries : World, United States, Canada
World Pathology: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) ? Pipeline Review, H1 2012
- $ 2 000
- Company report
- April 2013
- by Global Markets Direct
This report provides data on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with latest updates, and special features on late-stage and ...
- Industries : Pathology
- Countries : World
World Pathology: Chronic Plaque Psoriasis - Pipeline Review, H1 2012
- $ 2 000
- Company report
- April 2013
- by Global Markets Direct
This report provides data on the therapeutic development for Chronic Plaque Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...
- Industries : Pathology
- Countries : World
Pathology in United States: Post-Traumatic Stress Disorder (PTSD) ? Pipeline Review, H1 2012
- $ 2 000
- Company report
- April 2013
- by Global Markets Direct
This report provides data on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews ...
- Industries : Pathology
- Countries : United States, World
World Pathology: Waldenstrom Macroglobulinemia - Pipeline Review, H1 2012
- $ 2 000
- Company report
- April 2013
- by Global Markets Direct
This report provides data on the therapeutic development for Waldenstrom Macroglobulinemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key ...
- Industries : Pathology
- Countries : United States, World
Therapy in United States: Post Menopausal Osteoporosis - Pipeline Review, H1 2012
- $ 2 000
- Company report
- April 2013
- by Global Markets Direct
This report provides data on the therapeutic development for Post Menopausal Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key ...
- Industries : Pathology
- Countries : World
Kosovo Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : World
Peru Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2004 To 2029
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : Peru, World
Saint Vincent Post-traumatic Stress Disorder, 70+ Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : World
Trinidad & Tobago Peptic Ulcer Disease, 45-59 Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : World
Iran Protein-energy Malnutrition, 70+ Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : Iran, World
Congo-brazzaville Peptic Ulcer Disease, 45-59 Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : World
Palau Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : World
Iraq Prostate Cancer, 45-59 Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : Iraq, World
Cote D`ivoire Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : World
Mali Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : Mali, World
» Download Public Reports
About 1 400 reports
Company Report: Pathology in The United States for Year 2013
- Company report
- May 2013
- 6 pages
World Pharmaceutical Industry Statistics
April 2013The Swazi Pharmaceutical Industry
May 2013Global Pharmaceutical Sector Overview
April 2013» Read our Company Profiles
75 CompaniesNovartis Inc.
SwitzerlandGlaxoSmithKline P.L.C.
United StatesGlaxoSmithKline PLC
United KingdomEli Lilly and Co.
United StatesBayer AG
GermanyReportlinker.com © Copyright 2013. All rights reserved.
